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Summary
Hypertension is one of the most prevalent vascular diseases in the general population and is a major contributor to cardiovascular
mortality and morbidity. Recent clinical trials have confirmed the benefits of treatment of hypertension to prevent stroke, congestive
heart failure, and left ventricular hypertrophy. Despite the availability of many newer agent, blood pressure continues to be
inadequately controlled in the majority of the hypertensive patients. There is still a lot of controversy in some of the issues in the
management of hypertension. The present article summarizes some of the recent studies and published guidelines in the management
of hypertension and provides some insight to these questions. Although the answers to some of these questions are still unclear,
ongoing large scale studies should soon provide additional answers to these questions. (HK Pract 1996; 18(4): 147-157)
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Introduction
Hypertension continues to be one
of the most common diseases treated
by the general physician. Hypertensive
individuals, even those with mild
elevation of blood pressure, are at
increased risk of cardiovascular disease,
whether or not symptoms are present.
The causes of essential hypertension
which accounts for 90% of high blood
pressure, have not yet been
determined. Hypertension is defined
as the level of blood pressure where
investigation and treatment do more
good than harm. Elevated arterial
pressure is the only early indication of
hypertension, i.e. the disease attributed
to high blood pressure. The definition
of elevated blood pressure is varying
in different guidelines1'3. (Table 1) The
Table 1: Summary of guidelines for treating hypertension: (modified from
ref. [1-3])
Year
Definition of
Hypertension
Drug Treatment:
- without other risk
- with other risk
Goal
First-line Treatment
WHO/ISH
1993
SBP> 140 and/or
DBP>90
SBP>160and
DBP>95
SBP>1 40 and/or
DBP>90
BP<1 30/80
BP<140/90 (elderly)
D,BB,ACEI,CCB,AB
AB
JNC
1992
SBP> 140 and/or
DBP>90
BP> 150/95
BP>1 40/90
BP< 140/90
D, BB
BHS
1993
SBP>1 60 and/or
DBP>90
SBP>160
DBP>100
DBP>90
DBP< 90 and/or
possibly SBP< 160
D, BB or D, BB
ACEI. CCB, AB
AB=<x,-blockers, ACEI=angiotensin converting enzyme inhibitor, BB=p-blocker, CCB=calcium
channel blocker, D=diuretic
WHO=World Health Organization, ISH=lnternational Society of Hypertension, JNC=Joint
National Committee, BHS=British Hypertension Society
(Continued on Page 149)
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conventional definition of hypertension
is based on diastolic blood pressure
(DBP). On the other hand, systolic
blood pressure (S8P) elevation is
associated with equally sreat or sreater
risk when compared to DBP4. In general,
blood pressure is considered to be
abnormal if the DBP is above 90mmH3
and the SBP is above 140 mmHg when
measured at rest, relaxed condition.
However, there are several common
questions regarding the management of
hypertension: 1. Why is hypertension
treated? 2. What is the threshold for
initiation of drug therapy? 3. How far
should blood pressure be lowered? 4.
What are the physiologic effects of long
term hypertension control? 5. How
should blood pressure be lowered?
and 6. Is there a role for multiple drug
therapy?
Some of the answers to these
questions are not available and are
important area of recent ongoing
hypertensive research.
Why is hypertension
treated?
Hypertensive patients have
increased overall mortality and
increased incidence of other
complications (Figure 1). Furthermore,
it is clear that high blood pressure
frequently coexists with other risk
factors as part of a syndrome of
cardiovascular, neuroendocrine and
metabolic abnormalities (Table 2).
Thus, hypertension is only one of a
number of risk factors for cardiovascular
diseases. It should not be treated in
isolation from these other factors.
Hence, the primary goal of treating
hypertension and associated risk factors
is to reduce the major cardiovascular
mortality and morbidity i.e. stroke and
coronary artery disease (CAD). As
shown by the epidemiological studies
and the treatment trials, lowering of DBP
(5-6 mmHg) has resulted in a reduction
in the incidence of stroke (38-40%),
CAD (16%) and vascular mortality
(21%) (Table 3)b. Treatment benefits
Figure 1: Diagram of the relationship between different risk factors and
morbidity. DM = diabetes mellitus, Ml = myocardial infarction, PVD
= peripheral vascular disease
Llpids Smoking Hypertension
DM
\
PVD Stroke
/^^
f Vascular damage
\from blood pressure/1
/ *^*~~~^
si-
Kidney
damage
Table 2: The Hypertension Syndrome
High blood pressure
Dyslipidemias
Insulin Resistance
Truncal obesity
Microalbuminuria
Increased activity of coagulation factors
Reduced arterial compliance
Hypertrophy and altered diastolic function of left ventricle
Table 3: Summary of the effect of anti-hypertensive drug therapy on
coronary artery disease, stroke, and vascular mortality from meta-
analysis of 17 randomised studies (modified from ref. [5])
No. of event,
active therapy
Death Total
No. of event,
control
Death Total
Risk reduction^
(95% Cl)
Death Total
No. of patients
Coronary artery disease
Stroke
Total vascular mortality
23847
470 934
140 525
768
23806
560
234
964
1104 16(5-26)
835 40(26-51)
21 (13-28)
16 (8-23)
38(31-45)
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relate to the degree of BP elevation and
appear to be greater with larger
reductions in BP. Several large studies
also document treatment benefits for
mild hypertension6'8. Furthermore,
treatment benefits of isolated SBP
elevation in elderly are also well
documented9'10. Active therapy for
elevated blood pressure has been
shown to reduce relative risk equally in
men and women with regard to stroke,
CAD and other cardiovascular events11.
Several studies have addressed the
value of reducing blood pressure in the
elderly and confirmed the benefits of
treatment at least up to the age 75-80
years9'10. In summary, it appears that
treatment benefits accompany reductions
of SBP, DBP, and isolated systolic
hypertension in both men and women
and in elderly.
What is the threshold
for initiation of drug
therapy?
There is no clearly defined
threshold level of blood pressure
above which risk becomes apparent as
shown by prospective observational
studies. The Ions term risks for the
development of cardiovascular disease
increase with every increment of blood
pressure. Within a range of diastolic
pressure which many would consider
normal, there is a doubling of risk of
stroke and CAD18. Recently, guidelines
on threshold for initation of drug
therapy have been published and these
are summarized in Table 11'3. The
question of when to administer drugs
to young people with persistently raised
DBP>100 mmHg is now less controversial.
Younger individuals with a DBP in the
range of 90-99mmHg should also be
considered candidate for starting
antihyertensive drug therapy especially
if there is evidence of target organ
damage or with coexisting risk factors
(male, smokers, dyslipidaemia, diabetes,
renal disease and strong family history
of premature CAD)3. Individuals with
borderline hypertension but otherwise
healthy are at little short term risk and
will not be endangered by postponement
of drug therapy. They should be
continued on non-pharmacological
therapy and observed regularly. When
blood pressure does not fall during
continuing observation and non-
pharmacological therapy, the case to
start drug therapy is strong (Figure 2).
Similar to younger individuals,
hypertension in the elderly is a major
risk factor for cardiovascular mortality
and morbidity. These risks are magnified
in the elderly, probably because of the
higher prevalence of associated
cardiovascular risk factors and events".
Furthermore, systolic hypertension in
elderly is not benign and is a more
potent risk factor than increase in DBP14.
Among elderly individuals (65-74
years), a sustained SBP of > 160 mmHg
is an indication for pharmacological
treatment independent of the level of
DBP3. Little is known about how best
to manage hypertension in very elderly
individuals (>80 years).
How far should blood
pressure be lowered?
This question is controversial.
Epidemiological data indicate that the
relationship between the blood
pressure and cardiovascular risk is linear,
i.e., the lower the DBP, the lower the risk
of stroke and CAD4'5. Theoretically, it
appears that the lower the blood
pressure achieved by treatment, the
better. However, a retrospective study
Figure 2: Management schemes of hypertension. DBP = Diastolic blood
pressure, SBP = Systolic blood pressure, (modified from ref.
[2])
DBP
90-99mmHg >100mmHg
Persistent increase despite
1
No risk factor
1
coexisting
non-drug treatment |
I
risk factor or target organ damage
I \, f
observe Drug treatment I
Elderly SBP
160-199mmHg >200mmHg
Persistent increase despite non-drug treatment
DBP<95mmHg 1) coexisting risk factor or target organ damage
2) DBP>95mmHg
T
Observe Drug treatment
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showed that aggressive lowering of DBP
might lead to increase in coronary
events in patients with established CAD.
Thus concerns have been raised that
lowerins DBP may increase the risk of
myocardial ischemia by lowering
diastolic perfusion pressure in the
coronary circulation, mainly in patients
with left ventricular hypertrophy and
CAD, the so-called J-curve hypothesis
(Figure 3)15'16 Diastolic blood pressure
below 85 mmHg during treatment also
has greater cardiovascular morbidity
than patients in the 85-90mmHg
range15. An alternative explanation for
increased morbidity in those with lower
blood pressure on treatment is that
patients in this subgroup have a lower
pressure not only because of active anti-
hypertensive treatment, but also
because they have subclinical heart
disease. Observation of the J-curve
phenomenon in placebo or untreated
groups of hypertensive patients may
support this explanation. The absence
of a J-curve in older patients with
isolated systolic hypertension (SHEP)9
suggests that treatment-related
reduction in DBP to levels below
80 mmHg does not have to lead to
increased morbidity from CAD. A
tendency towards lower morbidity
even in actively treated patients with
low blood pressure is supported by
TOMHS17.
In the absence of studies which
document that a reduction of DBP to
below 85-90mmHg increases the
efficacy of treatment, the goal for DBP
reduction cannot be more closely
specified than below 90 mmHg.
Documentation is even less complete
with regard to optimal treatment goals
for SBP. Among middle aged
hypertensive patients it appears
reasonable to aim for a SBP below
140 mmHg. For elderly patients, a target
SBP below 160 mmHg can be
suggested. Different guidelines1'3 have
different target blood pressures (Table
1). An appropriate aim therefore is to
reduce the DBP to < 90 mmHg and SBP
to < 140 mmHg for young patients or
< 160 mmHg for elderly. Reductions of
blood pressure beyond 125/85 mmHg
are a matter of clinical judgement. In
certain patients, such as those with
Figure 3: The "J-shaped" curve of drug treatment of DBP. (modified reference
[16]) DBP = Diastolic blood pressure, Ml = myocardial infarction
Ml deaths/1000
patients yrs
<78 78-80 80-83 84-85 86-87 88-89 90-91 92-93 >94
DBP
Table 4: Lifestyle modification for hypertension control and/or overall
cardiovascular risk (modified from ref, [2-3])
- Lose weight if overweight
- Avoid excessive alcohol
- Exercise (aerobic) regularly
- Reduce sodium intake
- Maintain adequate dietary potassium, calcium and magnesium intake
- Stop smoking and reduce dietary satured fat and cholesterol intake
diabetes mellitus, blood pressure
should be reduced as much as possible
to reduce renal complications (e.g.
120/70 mmHg ), but those with CAD
should not. The Hypertension Optimal
Treatment (HOT) study, which randomises
patients to different target blood
pressure, is expected to clarify the
target blood pressure for anti-
hypertensive therapy18.
How should blood
pressure be lowered?
Pharmacological antihypertensive
therapy should be instituted only when
sustained hypertension has been
confirmed and non-drug measures fail.
Lifestyle changes (Table 4) are effective
and are recommended for both
hypertensive and normotensive
individuals with a strong family history.
Risk factors such as diabetes and
dyslipidaemia should also be controlled.
The choice of antihypertensive agent
remains ill defined. Diuretics and p-
blockers have less than ideal side-effect
profiles but have been proven in many
primary prevention trials to reduce
cardiovascular morbidity and mortality6-7.
Although newer agents are better
tolerated and have fewer metabolic
side-effects, their preventive efficacy
remains to be proven. The best
approach is to tailor therapy to the
patient with the consideration of
coexisting diseases, side effect profile
and presence or absence of
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contraindication. Diuretics, (3-blockers,
a^blockers, calcium antagonists or
angiotensin converting enzyme (ACE)
inhibitor can be used as first line agent
when appropriate (Table 5).
Diuretics
Ac/vantages. Diuretics remain
important, they are cheap, effective and
particularly useful in older patients and
those with incipient heart failure. Low
dose thiazide diuretic, especially in
combination with a potassium sparing
diuretic, has been extensively proven
in primary preventive trials to reduce
strokes. This therapy is especially useful
in the elderly in the prevention of CAD
as compared to a beta-blocker6.
Primary cardiac arrest is also reduced
with this therapy19.
Disadvantages. Diuretic therapy
requires monitoring for adverse effects
on serum potassium, glucose and lipid
levels.
p-blockers
Advantages. p-blockers have been
used in large clinical tr ials with
documented benefit. They have a
particular role in younger individuals
who are anxious, non-smokers, and
patients with CAD in whom (3-blockers
are indicated for angina. They also have
the additional benefits of a secondary
preventive effect against death and re-
infarction in patients who have suffered
a myocardial infarction80.
Disadvantages, p-blockers have
adverse metabolic effects with
worsening in insulin sensitivity and can
cause glucose intolerance. Those
without intrinsic sympathomimetic
activity raise triglycerides and low
density lipoprotein cholesterol level.
ACE inhibitors
Advantages. ACE inhibitors are
efficacious, safe and have been shown
to improve survival in patients with
impaired left ventricular function21 and
delay the need for renal dialysis in
patients with diabetic nephropathy22.
Table 5: Guideline for selecting initial therapy
Clinical situation
Requires special Relatively or absolutely
Preferred monitoring contraindication
Cardiovascular
angina pectoris
bradyarrhythmia
heart failure
hypertrophic
cardiomyopathy
peripheral
vascular disease
acute myocardial
infarction
Renal
bilateral renal
artery stenosis
renal failure
Other
- Asthma, COAD
- DM
Dyslipidemia
- Gout
BB, CCB
D, AECI
BB, verapamil
diltiazem
CCB, ACEI
BB, ACEI
CCB
CCB, BB ACEI
ACEI BB, D
AB, CCB BB, D
D
direct vasodilators
BB, verapamil, diltiazem
CCB
D, direct vasodilators
BB
direct vasodilators
ACEI
D*
BB
AB = a^blocker, ACEI = angiotensin converting enzyme inhibitor, BB = p-blocker,
CCB = calcium channel blocker, D = diuretic. *Diuretic may have reduced efficaciousness.
More rapid reversal of left ventricular
hypertrophy is observed compared
with other hypertensive treatments (see
below). ACE inhibitor is shown to
prevent the progression and the
development of diabetic nephropathy23.
Disadvantages. ACE inhibitors
cause bothersome dry cough in
significant proportion of patients. Other
side effects such as hyperkalemia, skin
rash and renal impairment are relatively
infrequent.
Calcium channel blockers
Advantages. The older calcium
channel blockers such as verapamil,
nifedipine and diltiazem have been
extensively used and long acting once
or twice daily formulations are now
available. Second-generation agents
which are newer dihydropyridine
analogues, may have advantages over
the first generation in terms of the
potential for once-daily administration,
vascular selectivity, and better side-
effect profile.
Disadvantages. Ankle edema and
headache are common complications.
The long term safety of this group of
drug is unclear. Recent data suggest that
high dose, short acting preparation of
nifedipine may be harmful and
associated with two-fold increased risk
of myocardial infarction in an
uncontrolled study. However, they
should not be considered as harmful
until further proof from the other
ongoing prospective randomized trials
is available24.
arblockers
Advantages, a., -blockers may be
useful in patients with dyslipidemia as
these agents tend to have either a
neutral or beneficial effect on plasma
lipid levels. They also are useful in
patients with prostatism.
Disadvantage. Postural hypotension
and dizziness are common side effects
especially in elderly.
(Continued on Page
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What are the physiologic
effects of long term
blood pressure control?
The optimal management of
hypertension extends beyond
reduction of blood pressure to ultimate
therapeutic goal of preventing target-
organ damage, including left ventricular
hypertrophy (LVH), atherosclerosis
(CAD and stroke), and renal failure.
Left ventricular hypertrophy (LVH)
Echocardiographic studies have
revealed that as many as 50% of
asymptomatic patients who have
mild-to-moderate hypertension have
LVH25'26. The presence of LVH is a
powerful predictor of cardiovascular
morbidity and mortality, particularly for
myocardial infarction, congestive heart
failure, ventricular arrhythmia and
sudden death25. Hemodynamic
overload from long-standing systemic
hypertension is the primaryfactor in the
pathogenesis of LVH, but non-
hemodynamic factors such as various
growth factors, proto-oncogenes and
cell growth-regulating gene, may play a
significant role as well. Both the
sympathetic nervous system and the
renin-angiotensin system (RAS) may
activate these cellular growth
mechanism and contribute to LVH.
Effective anti-hypertensive therapy
can prevent or even reverse established
LVH. Regression of LVH leads to
improved left ventricular filling and
contractility, enhanced coronary
reserve and reduce arrhythmia. The
Framingham Study showed that LVH
regression is associated with 25% risk
reduction in cardiovascular events26.
Meta-analyses showed that all drug
groups-ACE inhibitor, p-blockers,
calcium channel blockers and diuretics
significantly reduced LVH27. Some
drugs e.g. ACE inhibitor, may
theoretically be more effective because
they inhibit specific cellular mechanism
in addition to blood pressure lowering.
The large trials which used ECG criteria
for LVH found that diuretics based
therapy appears to have a favourable
effect on more pronounced LVH,
However, meta-analyses of
echocardiographic studies for LVH
showed that ACE inhibitors seem to be
more effective than other agents27.
Current ongoing large, well controlled,
comparative studies (e.g. PRESERVE
study) will provide a better answer
concerning the long term effects of
pharmacological blood pressure
lowering therapy and its long term
effects on LVH.
Atherosclerosis
Hypertension accelerates athero-
genesis by altering the biology of the
vascular endothelium and smooth
muscle. Hypertension is also associated
with abnormalities of lipid and insulin
metabolism, impaired arterial
compliance and increased production
of vasoactive substances and growth
factors that promote cellular
metabolism58. Anti-hypertensive
therapy may retard atherogenesis by
reversing one or more of these factors
through blood pressure lowering or
other direct mechanism (Table 6).
Renal Failure
Hypertension is the leading cause
of renal failure and tends to accelerate
the progression of renal failure
regardless of the underlying causes.
Treatment of systemic hypertension is
unequivocally beneficial in slowing the
progression of diabetic nephropathy.
Both ACE inhibitor and calcium
channel blocker produce comparable
reductions in proteinuria and a similar
rate of decline in GFR!2'S3'2'. Reduction
in BP is an important factor in slowing
the rate of progression of chronic renal
failure. Theoretically, ACE inhibitors
offer vasodilating effect and reduce
intraglomerular capillary pressure, may
have additional renoprotective effect.
However, there is currently no data to
suggest which agents may be more
effective than others in this respect.
Is there a role for multiple
drug therapy?
A recent study conducted in
Europe reported that of over 11,000
hypertensive patients being treated by
Table 6: Summary of the effect of anti-hypertensive agents on factors related to
atherosclerosis
Lipids
D
BB
CCB 0
ACEI 0 or +
AB +
RAS
-
0
0
+
0
Anti-proliferative Insulin Arterial
effect resistance compliance
0 0
0 - +
+ 0 or + +
+ + +
+? + +?
Overall
effect
Possibly-
?
+
+
+
Key: + = favorable effect, - = unfavourable, O = not effect.
AB = 01,-blockers, ACEI = angiotensin converting enzyme inhibitor, BB = p-blocker,
CCB = calcium channel blocker, D = diuretic, RAS = Renin-angiotensin-system
(Continued on Page 157)
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their general practitioners with
monotherapy, only about one-third had
a DBP <90mmHg, leavins two-thirds
inadequately controlled. This may seem
surprising, but is by no means confined
to Europe and is leading to
reconsideration in the use of
combination therapy, with an aim to
increase efficacy but minimise side
effects. Drugs have different primary
actions, selective use of combination of
therapy may have synergistic effect and
counteract their own side-effects (Table
7). Furthermore, combination therapy
may allow the use of lower dose of
each druss to reduce their side-effects.
Thus, drugs for use in combination can
maximise antihypertensive efficacy
while minimising side effects, and we
may be seeing fixed combination
tablets for once or twice daily
administration in wider use in the near
future.
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